Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3421670 | 0.98 | EPHX1 (0.38) | EPHX1SMN1; SMN2LMNAALDH1A1HSD17B10 | |
| SCHEMBL3422314 | 0.98 | EPHX1 (0.38) | EPHX1SMN1; SMN2LMNAALDH1A1HSD17B10 | |
| SCHEMBL3417847 | 0.98 | EPHX1 (0.38) | EPHX1SMN1; SMN2LMNAALDH1A1HSD17B10 | |
| SCHEMBL3200589 | 0.93 | EPHX1 (0.41) | EPHX1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1261448 | 0.86 | EPHX1 (0.35) | EPHX1 | |
| SCHEMBL29010354 | 0.86 | EPHX1 (0.35) | EPHX1 | |
| SCHEMBL3420555 | 0.85 | SMN1; SMN2 (0.39) | EPHX1SMN1; SMN2LMNAALDH1A1HSD17B10 | |
| SCHEMBL3416478 | 0.85 | SMN1; SMN2 (0.44) | EPHX1SMN1; SMN2LMNAALDH1A1HSD17B10 | |
| SCHEMBL617694 | 0.84 | — | — | |
| SCHEMBL5850277 | 0.84 | EPHX1 (0.36) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130712-A1 | ADAMANTANE DERIVATIVE, RESIN COMPOSITION USING THE SAME, AND RESIN CURED PRODUCT | IDEMITSU KOSAN CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130712-A1 | ADAMANTANE DERIVATIVE, RESIN COMPOSITION USING THE SAME, AND RESIN CURED PRODUCT | ARCN1, APP, ADAM17 | EPHX1 55/4885SMN1; SMN2 963/4885LMNA 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.